Clinical Trial Update: DY002: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating DYME (DY002) as a selective staining agent for the anterior capsule during cataract surgery has been terminated; no efficacy or safet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cataract

Drugs mentioned

• DYME (DY001)

Snippet

Sponsor: Aqumen Biopharmaceuticals, N.A. | Conditions: Mature Cataracts | Phase 3 | Status: TERMINATED